|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
SG11201804178YA
(en)
|
2015-11-18 |
2018-06-28 |
Merck Sharp & Dohme |
Pd1 and/or lag3 binders
|
|
EP3848393A1
(en)
|
2016-05-18 |
2021-07-14 |
Boehringer Ingelheim International GmbH |
Antibody molecules for cancer treatment
|
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
TW202436356A
(zh)
|
2016-10-11 |
2024-09-16 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
PE20190911A1
(es)
|
2016-10-13 |
2019-06-26 |
Symphogen As |
Composiciones y anticuerpos anti-lag-3
|
|
EP3541841B1
(en)
|
2016-11-18 |
2024-09-11 |
Les Laboratoires Servier |
Anti-pd-1 antibodies and compositions
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
AU2018219909B2
(en)
|
2017-02-10 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
|
|
BR112019021032A2
(pt)
*
|
2017-04-05 |
2020-05-05 |
Boehringer Ingelheim International Gmbh |
terapia combinada anticâncer
|
|
CA3185303A1
(en)
|
2017-04-05 |
2018-10-11 |
Symphogen A/S |
Combination therapies targeting pd-a, tim-3, and lag-3
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
US20210340250A1
(en)
|
2017-05-30 |
2021-11-04 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
KR102713203B1
(ko)
|
2017-05-30 |
2024-10-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Lag-3 양성 종양의 치료
|
|
KR20240155979A
(ko)
|
2017-05-30 |
2024-10-29 |
브리스톨-마이어스 스큅 컴퍼니 |
항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
|
|
CA3061053A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Boehringer Ingelheim International Gmbh |
Anti-cancer combination therapy
|
|
WO2019025545A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
|
|
WO2019120269A1
(zh)
*
|
2017-12-22 |
2019-06-27 |
江苏恒瑞医药股份有限公司 |
Lag-3抗体药物组合物及其用途
|
|
CN109970856B
(zh)
*
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
|
WO2019152574A1
(en)
*
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
|
|
WO2019165195A1
(en)
*
|
2018-02-22 |
2019-08-29 |
Srivastava Satish |
Combination therapy for the treatment of cancer
|
|
FR3078536A1
(fr)
*
|
2018-03-05 |
2019-09-06 |
Peptinov Sas |
Composition vaccinale anti-pd-1
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
KR102825164B1
(ko)
|
2018-03-27 |
2025-06-26 |
브리스톨-마이어스 스큅 컴퍼니 |
자외선 신호를 사용한 단백질 농도의 실시간 모니터링
|
|
CA3099547A1
(en)
|
2018-05-07 |
2019-11-14 |
Reshma Abdulla RANGWALA |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
SG11202009986QA
(en)
|
2018-05-07 |
2020-11-27 |
Genmab As |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
JP2021527082A
(ja)
*
|
2018-06-11 |
2021-10-11 |
イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ |
新規な免疫チェックポイント阻害剤
|
|
SG11202100693UA
(en)
*
|
2018-07-26 |
2021-02-25 |
Bristol Myers Squibb Co |
Lag-3 combination therapy for the treatment of cancer
|
|
JP7467438B2
(ja)
|
2018-10-18 |
2024-04-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｒｓｖ抗体の製剤及びその使用方法
|
|
CA3117016A1
(en)
|
2018-10-19 |
2020-04-23 |
Bristol-Myers Squibb Company |
Combination therapy for melanoma
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
CN113015748B
(zh)
|
2018-10-31 |
2025-12-12 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
AU2019374748A1
(en)
*
|
2018-11-05 |
2021-05-27 |
Merck Sharp & Dohme Llc |
Dosing regimen of anti-LAG3 antibody and combination therapy with anti-PD-1 antibody for treating cancer
|
|
CN113316458B
(zh)
*
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
WO2020097141A1
(en)
|
2018-11-07 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
|
TWI894135B
(zh)
|
2019-01-25 |
2025-08-21 |
德商百靈佳殷格翰國際股份有限公司 |
編碼ccl21之重組棒狀病毒
|
|
WO2020172658A1
(en)
|
2019-02-24 |
2020-08-27 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
|
JP2022526166A
(ja)
*
|
2019-03-29 |
2022-05-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗癌併用療法
|
|
EP3947455A1
(en)
*
|
2019-03-29 |
2022-02-09 |
Boehringer Ingelheim International GmbH |
Anticancer combination therapy
|
|
US20200318200A1
(en)
|
2019-04-02 |
2020-10-08 |
The Brigham And Women's Hospital, Inc. |
Methods for Identifying Progression of a Primary Melanoma
|
|
EP3969040A1
(en)
*
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
|
US20220220430A1
(en)
|
2019-05-23 |
2022-07-14 |
Bristol-Myers Squibb Company |
Methods of monitoring cell culture media
|
|
WO2020243563A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures for suitability to immuno-oncology therapy
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
CN114174537A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
细胞定位特征和组合疗法
|
|
CN114008080B
(zh)
*
|
2019-06-12 |
2023-06-09 |
南京金斯瑞生物科技有限公司 |
抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法
|
|
CN112121169B
(zh)
*
|
2019-06-24 |
2023-10-24 |
广州再极医药科技有限公司 |
用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂
|
|
EP3998081A4
(en)
|
2019-07-05 |
2023-07-12 |
Ono Pharmaceutical Co., Ltd. |
TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
|
|
WO2021005546A1
(en)
|
2019-07-09 |
2021-01-14 |
Cadila Healthcare Limited |
Antibodies to human programmed death receptor pd-1
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
JP7771749B2
(ja)
|
2019-08-08 |
2025-11-18 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
CN111420049A
(zh)
*
|
2019-08-22 |
2020-07-17 |
Biocad股份公司 |
抗-pd1抗体prolgolimab的水性药物组合物及其应用
|
|
AU2020345655A1
(en)
*
|
2019-09-11 |
2022-02-24 |
Boehringer Ingelheim Io Canada, Inc. |
Methods of treating cancer by the use of PD-1 axis inhibitors and anti-periostin antibodies
|
|
WO2021055994A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
TWI878355B
(zh)
*
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
CN115942973A
(zh)
|
2019-11-08 |
2023-04-07 |
百时美施贵宝公司 |
用于黑色素瘤的lag-3拮抗剂疗法
|
|
CN110950966B
(zh)
*
|
2019-12-13 |
2020-12-11 |
启辰生生物科技(珠海)有限公司 |
融合蛋白、编码核酸和细胞及用途
|
|
EP4100426A1
(en)
|
2020-02-06 |
2022-12-14 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
JP7565384B2
(ja)
|
2020-06-03 |
2024-10-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ＣＤ８０細胞外ドメインＦｃ融合タンパク質をコードするリコンビナントラブドウイルス
|
|
CN111808192B
(zh)
*
|
2020-06-05 |
2022-02-15 |
北京天广实生物技术股份有限公司 |
结合lag3的抗体及其用途
|
|
US20250262293A1
(en)
|
2020-07-07 |
2025-08-21 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
EP4204095A1
(en)
|
2020-08-28 |
2023-07-05 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
IL300916A
(en)
|
2020-08-31 |
2023-04-01 |
Bristol Myers Squibb Co |
Cell localization signature and immunotherapy
|
|
MX2023003414A
(es)
|
2020-09-24 |
2023-04-14 |
Merck Sharp & Dohme Llc |
Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y metodos de uso de las mismas.
|
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
|
AU2021364837A1
(en)
|
2020-10-23 |
2023-05-25 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
CN117580859A
(zh)
|
2020-11-17 |
2024-02-20 |
思进股份有限公司 |
用图卡替尼和抗pd-1/抗pd-l1抗体的组合治疗癌症的方法
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022146947A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
MX2023007650A
(es)
|
2020-12-28 |
2023-09-11 |
Bristol Myers Squibb Co |
Metodos de tratamiento de tumores.
|
|
CA3210196A1
(en)
|
2021-01-29 |
2022-08-04 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
US20240181052A1
(en)
|
2021-03-29 |
2024-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
WO2022216979A1
(en)
|
2021-04-08 |
2022-10-13 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
WO2022240741A1
(en)
|
2021-05-12 |
2022-11-17 |
Dana-Farber Cancer Institute, Inc. |
Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
|
|
AR126161A1
(es)
|
2021-06-17 |
2023-09-27 |
Boehringer Lngelheim Int Gmbh |
Moléculas de fijación triespecíficas novedosas
|
|
MX2024000674A
(es)
|
2021-07-13 |
2024-02-07 |
BioNTech SE |
Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
|
|
US20250002600A1
(en)
|
2021-10-06 |
2025-01-02 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination therapy
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
CN118176214A
(zh)
|
2021-10-29 |
2024-06-11 |
百时美施贵宝公司 |
血液癌症的lag-3拮抗剂疗法
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
MX2024008831A
(es)
|
2022-01-26 |
2024-07-25 |
Bristol Myers Squibb Co |
Terapia combinada para carcinoma hepatocelular.
|
|
MX2024010310A
(es)
|
2022-02-25 |
2024-08-28 |
Bristol Myers Squibb Co |
Terapia de combinacion para carcinoma colorrectal.
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CA3254481A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
USE OF ANTI-CLAUDIN-1 ANTIBODIES TO INCREASE T LYMPHOCYTE AVAILABILITY
|
|
JP2025509274A
(ja)
|
2022-03-09 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
治療用タンパク質の一過性発現
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
WO2023183317A2
(en)
*
|
2022-03-21 |
2023-09-28 |
Ab Therapeutics, Inc. |
Multispecific antibodies and uses thereof
|
|
AU2023269545A1
(en)
|
2022-05-12 |
2024-11-14 |
BioNTech SE |
Binding agents capable of binding to cd27 in combination therapy
|
|
EP4531916A1
(en)
|
2022-06-02 |
2025-04-09 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
EP4554677A1
(en)
|
2022-07-15 |
2025-05-21 |
Boehringer Ingelheim International GmbH |
Binding molecules for the treatment of cancer
|
|
EP4626446A1
(en)
|
2022-12-01 |
2025-10-08 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
AU2023403103A1
(en)
|
2022-12-01 |
2025-07-10 |
Medimmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
|
IL321098A
(en)
|
2022-12-14 |
2025-07-01 |
Astellas Pharma Europe Bv |
Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
|
|
IL321575A
(en)
|
2022-12-21 |
2025-08-01 |
Bristol Myers Squibb Co |
Combination therapy for lung cancer
|
|
CN121002071A
(zh)
|
2023-01-20 |
2025-11-21 |
勃林格殷格翰国际有限公司 |
IL-12 Fc融合蛋白
|
|
US20240299601A1
(en)
|
2023-02-17 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
CN115960834B
(zh)
*
|
2023-03-07 |
2023-06-09 |
浙江省肿瘤医院 |
一种pd-1/ptx联合pd-1耐药模型建立的方法
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
TW202509071A
(zh)
|
2023-05-12 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
能夠與ｏｘ４０結合之抗體、其變異體及其用途
|
|
CN121712571A
(zh)
|
2023-08-15 |
2026-03-20 |
百时美施贵宝公司 |
陶瓷羟基磷灰石色谱流通法
|
|
TW202535926A
(zh)
|
2023-10-30 |
2025-09-16 |
美商再生元醫藥公司 |
穩定抗體配製物
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
TW202541837A
(zh)
|
2023-12-08 |
2025-11-01 |
日商安斯泰來製藥公司 |
含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025132695A1
(en)
|
2023-12-19 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Recombinant rhabdovirus encoding for a gasdermin
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
US12521446B2
(en)
|
2024-02-27 |
2026-01-13 |
Bristol-Myers Squibb Company |
Anti-CEACAM5 antibody drug conjugates
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025226695A1
(en)
|
2024-04-23 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|